8-K: XOMA Acquires Royalty Interests in Three Women's Health Assets for $22 Million

XOMA Corporation has acquired royalty and milestone interests in three women's health assets, including XACIATO, Ovaprene, and Sildenafil Cream, for an upfront payment of $22 million.

Summary

• XOMA Corporation has purchased royalty and milestone rights for three women's health assets from Dar Bioscience for $22 million.
• The assets include XACIATO, a commercial product for bacterial vaginosis, and two investigational assets, Ovaprene, a contraceptive, and Sildenafil Cream for female sexual arousal disorder.
• XOMA will receive royalties on net sales of XACIATO, ranging from low to high single digits, and potential milestone payments.
• XOMA will also receive a 4% synthetic royalty on net sales of Ovaprene and a 2% synthetic royalty on net sales of Sildenafil Cream, which will decrease to 2.5% and 1.25%, respectively, upon XOMA achieving a pre-specified return threshold.
• The deal also includes a portion of a potential milestone payment from Bayer related to Ovaprene.
• XOMA may also make milestone payments to Dar upon achieving a pre-specified return threshold.

Sentiment

Score: 7

Explanation: The document presents a positive development for XOMA, with the acquisition of royalty interests in three promising assets. The deal is non-dilutive and provides both immediate and potential future revenue streams. However, the success of the assets is still subject to regulatory approvals and commercial success.

Positives

• XOMA has expanded its portfolio with three new assets in the women's health sector.
• The acquisition provides XOMA with immediate revenue from XACIATO, which is already commercially available.
• The deal includes potential for future revenue through milestone payments and royalties on Ovaprene and Sildenafil Cream.
• The transaction is non-dilutive, providing capital to Dar without diluting XOMA's existing shareholders.
• The acquired assets have the potential to create additional value for XOMA's shareholders.

Negatives

• The synthetic royalties on Ovaprene and Sildenafil Cream are initially low single-digit percentages.
• The reduction in royalty rates on Ovaprene and Sildenafil Cream after XOMA achieves a pre-specified return threshold could limit long-term upside.
• The success of Ovaprene and Sildenafil Cream is dependent on their successful development and commercialization.

Risks

• The success of the acquired assets is dependent on the commercial success of XACIATO and the successful development and regulatory approval of Ovaprene and Sildenafil Cream.
• There is no guarantee that the investigational compounds will become commercially available.
• The licensees may require substantial funds to continue development, which may not be available.
• There is no guarantee that there will be a viable market for the products in which XOMA has an ownership or royalty interest.
• If the therapeutic product candidates do not receive regulatory approval, XOMA's third-party licensees will not be able to market them.

Future Outlook

The company anticipates potential commercial payments from the acquired assets, but these are subject to the success of the products and regulatory approvals. XOMA disclaims any obligation to update any forward-looking statement, except as required by applicable law.

Management Comments

• Brad Sitko, Chief Investment Officer at XOMA, stated that each of the three assets represents a meaningful advance in the women's health category that has typically been under-represented and has significant growth potential.
• XOMA structured an attractive, non-dilutive royalty capital solution that provides Dar with additional financial resources to advance its pipeline through key catalysts and aligns with its stockholders, enabling them to participate in the future value created by XACIATO, Ovaprene, and Sildenafil Cream.

Industry Context

This acquisition aligns with the trend of royalty aggregators like XOMA investing in late-stage and commercial assets to generate revenue and potential future value. The focus on women's health addresses an area that has been historically under-represented in pharmaceutical development.

Comparison to Industry Standards

• XOMA's strategy of acquiring royalty interests is similar to other royalty aggregators like Royalty Pharma, which focuses on acquiring royalties on marketed and late-stage drugs.
• The acquisition of XACIATO, a commercial product, provides immediate revenue, which is a common goal for royalty aggregators.
• The synthetic royalty structure on Ovaprene and Sildenafil Cream is a common approach to mitigate risk while still participating in potential upside.
• The focus on women's health is a growing area of interest in the pharmaceutical industry, with companies like Organon and Bayer actively involved in this space.

Stakeholder Impact

• Shareholders may benefit from the potential revenue and value creation from the acquired assets.
• Dar Bioscience receives non-dilutive funding to advance its pipeline.
• Patients may benefit from the development and commercialization of new women's health therapies.

Next Steps

• XOMA will begin receiving royalties on XACIATO sales.
• XOMA will monitor the development and regulatory progress of Ovaprene and Sildenafil Cream.
• XOMA will potentially receive milestone payments based on the commercial success of XACIATO.
• XOMA may make milestone payments to Dar upon achieving a pre-specified return threshold.

Key Dates

Keywords

royalty, milestone, XACIATO, Ovaprene, Sildenafil Cream, women's health, biotechnology, licensing, pharmaceutical, commercialization